Literature DB >> 15530917

The A-1087IL-10 allele is associated with cardiovascular disease in SLE.

Guo-Zhong Fei1, Elisabet Svenungsson, Johan Frostegård, Leonid Padyukov.   

Abstract

The risk of cardiovascular disease (CVD) in SLE patients is very high. It is therefore surprising that IL-10 has been discussed both as pathogenic in SLE and as an atheroprotective cytokine. In contrast, TNF is believed to be atherogenic and we recently reported that raised activity in the TNF-system is implicated in SLE-related CVD. Twenty-six (aged 52 +/- 8 years) female patients with SLE and a history of CVD (myocardial infarction, angina, stroke or claudication) were compared with 26 age-matched SLE patients without CVD (SLE controls) or 26 age-matched population controls. The -1087IL-10 gene polymorphism was determined by PCR with restriction endonuclease mapping. Serum IL-10 and TNF-levels were determined by ELISA. The A allele frequency of -1087IL-10 gene in SLE/CVD was higher than in SLE controls (0.62 versus 0.42, p < 0.05). Ten (38%) of 26 SLE/CVD exhibited IL-10 AA genotype compared with five (19%) of 26 SLE controls. Serum IL-10 and TNF-levels were raised in SLE/CVD compared with SLE controls or population controls (p < 0.001). Furthermore, in SLE/CVD, a significantly reduced IL-10:TNF ratio was observed in patients with IL-10 AA genotype compared with AG or GG genotype (0.56 versus 0.77 versus 1.24, p < 0.05). In SLE controls and population controls, individuals with IL-10 GG genotype tended to have higher IL-10:TNF ratio. In conclusion, the A-1087IL-10 allele which has been reported to cause a lower capacity for IL-10 production could contribute to CVD in SLE. Furthermore, the IL-10 AA genotype is associated with reduced ratio of atheroprotective to atherogenic cytokines in SLE patients with CVD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530917     DOI: 10.1016/j.atherosclerosis.2004.07.026

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Polymorphisms of interleukin-10 genes on the risk of ischemic stroke in a meta-analysis.

Authors:  Guo-Ting Yin; Yi-Tong Ma; Ying-Ying Zheng; Yi-Ning Yang; Xiao-Mei Li; Zhen-Yan Fu; Jing-Zhan Zhang; Chuan-Fang Dai; Fen Liu; Bang-Dang Chen; Min-Tao Gai; Xiang Xie
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Management of cardiovascular complications in systemic lupus erythematosus.

Authors:  Carly Skamra; Rosalind Ramsey-Goldman
Journal:  Int J Clin Rheumtol       Date:  2010-02-01

Review 3.  IL-10 and TNFalpha genotypes in SLE.

Authors:  Patricia López; Carmen Gutiérrez; Ana Suárez
Journal:  J Biomed Biotechnol       Date:  2010-06-21

Review 4.  Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus.

Authors:  Hui Peng; Wei Wang; Mo Zhou; Rui Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2013-05-25       Impact factor: 2.980

5.  Functional inflammatory genotypes in ischemic stroke: could we use them to predict age of onset and long-term outcome?

Authors:  Stella Marousi; Anna Antonacopoulou; Haralambos Kalofonos; Panagiotis Papathanasopoulos; Marina Karakantza; John Ellul
Journal:  Stroke Res Treat       Date:  2011-05-29

6.  Relationship between interleukin-10 -1082A/G polymorphism and risk of ischemic stroke: a meta-analysis.

Authors:  Jun Jin; Wuying Li; Lingmei Peng; Jian Chen; Rong Li; Peihua Wu; Sheng Tan
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

7.  Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Dag Leonard; Elisabet Svenungsson; Johanna Dahlqvist; Andrei Alexsson; Lisbeth Ärlestig; Kimberly E Taylor; Johanna K Sandling; Christine Bengtsson; Martina Frodlund; Andreas Jönsen; Susanna Eketjäll; Kerstin Jensen-Urstad; Iva Gunnarsson; Christopher Sjöwall; Anders A Bengtsson; Maija-Leena Eloranta; Ann-Christine Syvänen; Solbritt Rantapää-Dahlqvist; Lindsey A Criswell; Lars Rönnblom
Journal:  Ann Rheum Dis       Date:  2018-03-07       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.